After hosting meetings with Inogen's CEO Scott Wilkinson and CFO Ali Bauerlein, Leerink analyst Danielle Antalffy is "even more confident" that the company remains on track to build upon its "solid" history of execution since becoming a public company, and is well-positioned to continue to deliver consistent "beat and raise" quarters. In the near-term, the analyst sees room for potential upside to Inogen's 2017 guidance given a steady adoption trend among homecare providers and management's conservative approach to issuing guidance for the lower visibility B2B businesses. She reiterates an Outperform rating and $90 price target on the shares.